OBJECTIVES: The price of a medicine should reflect the value it offers to patients, the healthcare system and society more broadly. However, with current pricing manufacturers can only set the price of a product based upon the cost per unit of that product. This may result in a price being set which society considers as being as ‘too high’ in certain indications. This apparent mismatch in value and cost can lead to patients being denied access to medicine in certain indications. METHODS: The implementation of a pricing model where there is differentiated value of a medicine across indications, line of therapy or if used as a mono/combination therapy requires the use of real world drug utilisation data. The Personalised Reimbursement Models project is at the forefront of the development and implementation of innovative pricing approaches in the UK.  This project includes identifying and developing the infrastructure required in order to introduce Multi-Indication Pricing (MIP) into the NHS in the UK. We have worked alongside NHS Trusts and national bodies in a joint working project to validate and test the utility of the Systemic Anti-Cancer Therapy (SACT) dataset. RESULTS: This joint working project demonstrates that SACT has the potential to allow implementation of MIP in England. CONCLUSIONS: Following completion of this work we hope SACT will be used to introduce MIP in England - this will eliminate the administrative pharmacy burden of data collection for commercial schemes for cancer medicines, enabling medicines to be priced for the value they provide in each of their uses and ensure that patients are not disadvantaged due to having a condition potentially treatable by a product with multiple indications